Skip to main content
. 2016 Jun 7;24(2):73–80. doi: 10.3727/096504016X14586627440156

Figure 1.

Figure 1

(A) Overall survival. (B) Comparison of survival between patients in complete remission (CR) and patients not responsive to mitoxantrone–etoposide (NR).